In this opening segment, the panel discusses how patients with desmoid tumor typically present and how referral pathways have evolved in recent years.
Back
Optimizing Treatment of Desmoid Tumor Through Multidisciplinary Strategies
In this OncLive Peer Exchange, Richard F. Riedel, MD; Jason Sicklick, MD; and Kathleen Polson, NP, discuss contemporary multidisciplinary management of desmoid tumor across the full care continuum. The panel explores evolving referral patterns, diagnostic confirmation, and the clinical implications of molecular findings, while highlighting the shift away from routine upfront surgery toward observation and systemic therapy when appropriate. They examine how patient reported outcomes influence treatment thresholds, outline strategies for managing therapy-related adverse events, and address fertility and reproductive counseling considerations in younger patients. Emphasizing structured multidisciplinary collaboration and individualized decision making, the discussion underscores how integrating tumor biology, symptom burden, and patient priorities can improve coordination of care and optimize outcomes in desmoid tumor management.
Optimizing Treatment of Desmoid Tumor Through Multidisciplinary Strategies
Episodes
All
All
Experts unpack desmoid tumor diagnosis, watchful waiting, and when systemic therapy beats surgery, highlighting NCCN-guided multidisciplinary care.
Explore how desmoid tumor genetics guide diagnosis and FAP screening, why APC testing matters, and when molecular profiling shapes monitoring decisions.
Explore updated desmoid tumor care: NCCN-backed targeted drugs like nirentasertib, plus when cryoablation or radiation fits.
Desmoid tumor care shifts from surgery to systemic options like gamma secretase inhibitors; experts weigh chemo, TKIs, and selective cryoablation or radiation.
Learn how tumor boards unite sarcoma experts—and how remote clinics join Zoom reviews, online panels, and fast second opinions.
Learn how clinics proactively manage oral cancer therapy toxicities—education, early follow-ups, and dose tweaks to control hand-foot, GI
Learn how clinicians proactively manage toxicities from targeted systemic cancer therapies, using early education, monitoring, and dose adjustments to maintain adherence.
Learn how clinicians address fertility risks from newer cancer therapies, discuss ovarian toxicity, pregnancy avoidance, and when to refer for preservation.
Learn how clinicians judge tumor treatment success beyond scan shrinkage, using symptoms, stable disease, and surveillance insights from desmoid tumor trials.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Zidesamtinib in Pretreated ROS1+ NSCLC
2
FDA Accepts NDA for Daraxonrasib in Previously Treated Metastatic Pancreatic Cancer
3
Dr Patel on the Unmet Need in EGFR+ Transformed Small Cell Lung Cancer
4
Dr Galsky on Systemic Therapy Advances in Muscle-Invasive Bladder Cancer
5